ClinicalTrials.gg
CompletedNCT04452500SEVENUpdated Oct 27, 2026

Phase IIa Trial of a Selective Glucocorticoid Receptor Antagonist in the Treatment of Veterans With Posttraumatic Stress Disorder (PTSD) (Seven Study)

A Phase 2 interventional study of CORT108297 and Placebo in PTSD, sponsored by VA Office of Research and Development. Completed at 2 sites in United States. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by VA Office of Research and Development · Phase 2, Interventional, and Treatment

How we know

Updated Oct 27, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development — 56 open to participants now, 65 under way, 4 of them phase 3. Stress Disorders, Post-Traumatic · VA Office of Research and Development.

Enrollment
189th of 246
39 · median 87
Started
2022
with 21 others
Phase 2
23 of 263
5 open now
Registered
175th of 263
by date

Among the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, this one is the 189th largest by enrollment of the 246 interventional ones that give a count, is one of 22 that started in 2022, is one of 23 in phase 2, and was the 175th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

56 of the 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

51 more — sign in →

By country, each count listing its studies:

All 56 open studies →

Where they have run

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 263 studies in Stress Disorders, Post-Traumatic by VA Office of Research and Development, or all of them as a file.
02

Study summary

The purpose of this study is to test the drug CORT108297, which blocks the hormone cortisol, for treatment of PTSD in Veterans, and establish a safety profile that will inform the design of future studies.

Read the detailed description

This is a randomized, double-blind, placebo-controlled Phase IIa clinical trial to test the efficacy and safety of CORT108297- 180 milligrams daily for 7 days for PTSD symptoms in Veterans. Each of the two sites will enroll 44 Veterans with chronic PTSD. Participants first will undergo screening procedures, including a clinical psychological interview, self-report questionnaires, blood draw, and medical evaluations. If eligible, they will be randomized to either CORT108297 or placebo. The same procedures will be repeated at several in-person and virtual visits before, during and after taking the study drug or placebo for seven days. The key outcome measures will be obtained at baseline, day 7, 28, and day 56.

There is large body of evidence demonstrating that Posttraumatic Stress Disorder (PTSD) is associated with alterations in the stress hormone cortisol. There is also evidence that medications that block cortisol may be beneficial for treating PTSD and depression. This study will test a medication, CORT108297, which is from a new class of cortisol blockers which have no effect on other hormones. CORT108297 has been shown to have efficacy in preclinical CNS models and was well tolerated and safe in Phase I healthy volunteer studies making it a candidate for further development. Thus, the goal will be to complete a Phase IIa proof of concept trial of CORT108297 to focus on safety and tolerability and obtain pilot efficacy data to inform the design of future clinical trials.

03

Conditions studied

  • PTSD

Keywords

  • Glucocorticoids
  • Posttraumatic Stress Disorder
  • Quality of Life
04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
18 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of US military service
  • Capable of reading and understanding English
  • Able to provide written
  • Symptoms of post-traumatic stress disorder (must score 23 or greater on the CAPS-5 assessment at screening visit)
  • Men and pre-menopausal women must agree to use two forms of reliable , one of which is a barrier method
  • Participants who use an SSRI or SNRI medication for PTSD must be on a stable dose for 8 weeks before enrollment
  • Participants who use trazodone for sleep must be on a stable dose
  • Participants who use opiate pain medication must be on a stable dose
  • For participants who are in psychotherapy, treatment must be stable for 6 weeks

Exclusion criteria

Exclusion Criteria:

  • Alcohol use that meets criteria for Alcohol Use Disorder in past 3 months
  • Marijuana or other drug use that meets criteria for Substance Use Disorder in past 3 months
  • Ever diagnosed with: Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Obsessive-Compulsive Disorder, or Major Depressive Disorder with Psychotic Features
  • Experienced any psychologically traumatic event in the past 3 months
  • Currently using certain antidepressant medications such as doxepin or tricyclics
  • Currently using certain mood stabilizers, such as lithium
  • Currently using antipsychotic medication
  • High risk for suicide or violent behavior
  • Has sleep apnea and not using any treatment, such as continuous positive airway pressure (CPAP)
  • Currently using medication (oral or inhaled)
  • History of neurological disease
  • Angina, congestive heart failure or low blood pressure
  • Heart attack in the past 6 months
  • Heart block or irregular heartbeat
  • Kidney failure, liver failure or pancreatitis
  • Severe (COPD)
  • History of liver disease with lab results on or ALT more than 2 times the normal readings
  • History of kidney disease with lab results on less than 60 ml/min
  • History of additional risk factors for Torsades de pointes, such as heart failure, low potassium, or family history of a heart rhythm disorder called long syndrome
  • Use of certain medications that can affect heart rhythm
  • Use of certain medications that can interfere with the effects of the study drug
  • High blood pressure that is not controlled by medication
  • Diabetes that is not well-controlled
  • History of certain types of head injuries
  • Mild cognitive impairment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    CORT108297

    CORT108297- 180 milligrams (mg) daily for 7 days

    Drug: CORT108297

  • Placebo comparator
    Placebo

    Placebo- 180 milligrams (mg) daily for 7 days

    Drug: Placebo

Interventions

  • DrugCORT108297

    CORT108297- 180 milligrams (mg) daily for 7 days

  • DrugPlacebo

    Placebo- 180 milligrams (mg) daily for 7 days

06

What researchers measure

Primary outcomes

  1. Clinician Administered PTSD Scale for DSM-5 (CAPS)

    The CAPS is a 30-item interview that is the gold standard assessment for PTSD. The CAPS provides a dimensional and categorical measure of PTSD, and incorporates frequency and intensity of symptoms into a single severity score.

    Time frame: 56 days

  2. Frequency, Intensity, Burden of Side Effects (FIBSER)

    The FIBSER is a self-report 0-6 Likert-type scale that measures global frequency, intensity, and overall burden of side effects.

    Time frame: 56 days

Secondary outcomes

  1. Columbia Suicide Severity Rating Scale

    The C-SSRS is FDA approved for assessing severity and change of suicidality in drug studies.

    Time frame: 56 days

  2. PTSD Checklist for DSM-5

    The PCL is a validated self-report scale assessing PTSD symptoms corresponding to DSM-5.

    Time frame: 56 days

  3. World Health Organization Quality of Life (WHOQOL-BREF)

    The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original WHOQOL-100 instrument and is more convenient for use in large research studies or clinical trials.

    Time frame: 56 days

07

Study locations

2 sites
  • Tuscaloosa VA Medical Center, Tuscaloosa, AL
    Tuscaloosa, Alabama 35404, United States
  • San Francisco VA Medical Center, San Francisco, CA
    San Francisco, California 94121-1563, United States
08

References and documents

Individual participant data

Plan to share: Yes — For the proposed work final de-identified data from this project will be shared as widely as possible with the scientific community using UCSF DataShare (aka Dash). This self-service tool, available to any UCSF affiliated researcher, is a collaboration between University of California San Francisco's Library, and the UC Curation Center (UC3) at the California Digital Library and the UCSF Clinical and Translational Science Institute (CTSI).

Supporting information: Statistical analysis plan, Clinical study report

Time frame: Within 1 year of the end of the funding period.

Access criteria: After the raw data is made available on the Dash site, anyone will also be able to view the descriptive metadata used to index the data set. This information is publicly available to allow for maximum discoverability. Individuals wishing to access the data must agree to terms of use for the data set via a Data Use Agreement, and may have to meet additional requirements as set forth by the PI. The data will be permanently archived and available through the California Digital Library.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Jul 2026, 45 months.

Of 87 non-industry phase 2 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 59. This study's 45 months is close to that.

Counting every sponsor, half of 118 studies reached it within 38 months; a quarter within 23 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Jul 2026 and completion Dec 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jun 30, 2020
StartActual
Oct 15, 2022
Primary completionActual
Jul 31, 2026was Dec 2026
CompletionActual
Jul 31, 2026was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 27, 2026
Primary completion
Dec 31, 2026→Jul 31, 2026 (actual)
Oct 27, 2026
Study completion
Dec 31, 2026→Jul 31, 2026 (actual)
Oct 27, 2026
Enrollment
40 (estimated)→39 (actual)
Oct 27, 2026
Eligibility
1 inclusion criterion edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedSymptoms of PTSDpost-traumatic stress disorder (must score 23 or greater on the CAPS-5 assessment at screening visit)
Exclusion criteria
  • EditedHas sleep apnea and not using any treatment, such as continuous positive airway pressure (CPAP)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Recruiting→Completed
    Primary completion Dec 31, 2026→Jul 31, 2026 (now actual)
    Study completion Dec 31, 2026→Jul 31, 2026 (now actual)
    Enrollment 40 (estimated)→39 (actual)
    Eligibility 1 inclusion criterion edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedSymptoms of PTSDpost-traumatic stress disorder (must score 23 or greater on the CAPS-5 assessment at screening visit)
    Exclusion criteria
    • EditedHas sleep apnea and not using any treatment, such as continuous positive airway pressure (CPAP)
    + 6 other changes: identifiers, verification date, description, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04452500
Responsible party
Sponsor
First posted
Jun 30, 2020
Start date
Oct 15, 2022
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Oct 27, 2026

Study contacts

Thomas C. Neylan, MD
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion